Bronconex Acticap

Šalis: Naujoji Zelandija

kalba: anglų

Šaltinis: Medsafe (Medicines Safety Authority)

Veiklioji medžiaga:

Mometasone furoate 400ug (anhydrous)

Prieinama:

Organon (New Zealand) Limited

INN (Tarptautinis Pavadinimas):

Mometasone furoate 400 µg (anhydrous)

Dozė:

400 mcg/dose

Vaisto forma:

Powder for inhalation

Sudėtis:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Vienetai pakuotėje:

Inhaler, metered, DPI, (sample), 14 dose units

Klasė:

Prescription

Recepto tipas:

Prescription

Pagaminta:

MSD International GmbH (Singapore Branch)

Terapinės indikacijos:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Produkto santrauka:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Leidimo data:

2000-12-05